Asthma Treatment in a Population-Based Cohort: Putting Step-Up and Step-Down Treatment Changes in Context

Yawn, Barbara P.; Wollan, Peter C.; Bertram, Susan L.; Lowe, David; Butterfield, Joseph H.; Bonde, Denise; Li, James T. C.
April 2007
Mayo Clinic Proceedings;Apr2007, Vol. 82 Issue 4, p414
Academic Journal
OBJECTIVE: To assess the frequency and types of visits related to modifications in the Intensity of asthma medications. PATIENTS AND METHODS: We retrospectively reviewed the medical records of adults (aged 18–40 years) and children (aged 6–17 years) living in Olmsted County, Minnesota, to evaluate changes in asthma medications by dose and drug class and site and type of visit (routine vs unscheduled) at the time of changes. All records from all visits were reviewed for each patient to Identify asthma-related visits at all sites of care from January 1, 2002, through December 31, 2003. RESULTS: The study consisted of 397 adults and children, in 255 patients, 597 asthma medication changes occurred. Step-up changes usually occurred because of an exacerbation or loss of control of asthma and adhered to the medication hierarchy in the national asthma guidelines. Twenty step-up changes involved skipping inhaled corticosteroid (ICS) monotherapy and moving directly to combined ICSs plus a long-acting β-agonist (LABA). Lack of documentation of asthma symptom frequency or interference with activities made it impossible to determine whether these ‘skips’ were appropriate. Only 78 physician-directed step-down changes were documented, usually to a lower dose of combined ICSs and LABAs or a move from combined ICSs and LABAs to anti-inflammatory monotherapy. Patients initiated additional step-down changes between encounters. Step-down changes occurred at routine or follow-up asthma visits, but the limited number of such visits provided few opportunities for step. down care. CONCLUSION: The continuing episodic-style treatment of asthma aimed at exacerbation management facilitates step-up changes in asthma therapy. The dearth of asthma evaluation visits limited opportunities to step down use of asthma medications and to provide long-term asthma management.


Related Articles

  • Prescribe beta-2 agonist instead of extra steroids. Baines, Emma // GP: General Practitioner;1/12/2004, p11 

    Patients who do not respond to a 200mu g dose of fluticasone will benefit more from long-acting beta-2 agonists than from higher doses of inhaled corticosteroids, according to a meta-analysis. Researchers from New Zealand looked at data on fluticasone from seven trials involving 2,431...

  • Immunotherapy and Asthma. Fitzgerald, J. Mark // JAMA: Journal of the American Medical Association;10/6/89, Vol. 262 Issue 13, p1772 

    Presents a letter to the editor in the October 6, 1989 issue of the 'Journal of the American Medical Association,' noting the appropriate dose and mode of administration of corticosteroids in acute asthma.

  • Doubling the dose of budesonide versus maintainance treatment in asthma exacerbations. Filzgerald, J. M.; Becker, A.; Sears, M. R.; Mink, S.; Chung, K.; Lee, J. // Thorax;Jul2004, Vol. 59 Issue 7, p550 

    Background: Previous guidelines recommend doubling the daily dose of maintenance inhaled corticosteroid to treat or prevent progression of exacerbations of asthma. Methods: Over a 6 month period a cohort of patients were evaluated prospectively and randomised in a double blind controlled trial...

  • Clinical Significance of Asthma Clusters by Longitudinal Analysis in Korean Asthma Cohort. Park, So Young; Baek, Seunghee; Kim, Sujeong; Yoon, Sun-young; Kwon, Hyouk-Soo; Chang, Yoon-Seok; Cho, You Sook; Jang, An-Soo; Park, Jung Won; Nahm, Dong-Ho; Yoon, Ho-Joo; Cho, Sang-Heon; Cho, Young-Joo; Choi, ByoungWhui; Moon, Hee-Bom; Kim, Tae-Bum // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1 

    Background: We have previously identified four distinct groups of asthma patients in Korean cohorts using cluster analysis: (A) smoking asthma, (B) severe obstructive asthma, (C) early-onset atopic asthma, and (D) late-onset mild asthma. Methods and Results: A longitudinal analysis of each...

  • Impact of maternal use of asthma-controller therapy on perinatal outcomes. Cossette, Benoit; Forget, Amélie; Beauchesne, Marie-France; Rey, Évelyne; Lemière, Catherine; Larivée, Pierre; Battista, Marie-Claude; Blais, Lucie // Thorax;Aug2013, Vol. 68 Issue 8, p724 

    Background: Asthma during pregnancy usually requires treatment with controller medications about which more safety information is needed. The objectives are to assess the impact of the use of long-acting β2-agonists (LABAs) and the dose of inhaled corticosteroids (ICSs) during pregnancy on...

  • Soothing patient and parent qualms about inhaled corticosteroids. Salva, Paul S. // Contemporary Pediatrics;Sept2003, Vol. 20 Issue 9, p18 

    Relates the use of a dose-comparison chart between inhaled corticosteroids (ICS) and other antiasthmatic drugs in persuading parents and patients to use ICS. Reaction of parents and patients to the use of ICS medication; Drugs compared with ICS; Benefits of using the dose-chart comparison.

  • ADRENOCORTICOIDS (Oral Inhalation).  // Complete Guide to Prescription & Nonprescription Drugs 2012;2012, p14 

    The article presents information on oral inhalation adrenocorticoids, including its dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

  • ADRENOCORTICOIDS (Oral Inhalation). GRIFFITH, H. WINTER // Complete Guide to Prescription & Nonprescription Drugs 2012;2010, p14 

    The article presents information on adrenocorticoids (oral inhalation), a drug developed to treat and prevent symptoms in chronic bronchial asthma, including its dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

  • ADRENOCORTICOIDS (Oral Inhalation).  // Complete Guide to Prescription & Nonprescription Drugs 2012;2007, p14 

    The article presents information on adrenocorticoids (oral inhalation), a drug used for treatment for prevention of symptoms in patients with chronic bronchial asthma. The dosage and usage information is provided. The possible adverse reactions or side effects of the drug, warnings, and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics